

Review Article

The Effect of [Healthy Foods](#) ~~Diet~~ on Cardiovascular Diseases: [Part I](#), Cardiac Arrhythmias [Part-I](#)

Abstract

The heart is a mechanical pump, and it contracts in response to a bioelectrical signal, the action potential. The action potential originates in the sinus node cells, spreads through both atria, causing their contraction. The next stage of propagation is the atrioventricular (AV) node, which passes the signal to the ventricles with a slight delay to provide enough time for the atria to contract. ~~From the AV node, the bundle of His conducts the stimulus along the septal wall to the subendocardial Purkinje fibers, which then stimulate the ventricles, allowing their synchronized contraction.~~ Disturbances of action potential generation and/or conduction can lead to changes in the regular heart rhythm called arrhythmias. Cardiac arrhythmias are usually due to cardiovascular diseases. ~~Diet~~ [Healthy foods](#) impacts cardiac arrhythmias by reducing cardiovascular diseases. However, [healthy food](#) ~~diet~~ can also directly influence arrhythmia incidence and severity. The influence of diet as a low-cost intervention to improve cardiovascular health and reduce cardiac arrhythmias is discussed in this ~~2-part~~ manuscript. [Need some more details on the effect of diet on cardiovascular disease. Also conclusion.](#)

Keywords: [C](#)ardiac [A](#)rrhythmias, ~~f~~[F](#)ruits, ~~and V~~[V](#)egetables, ~~N~~[N](#)uts, ~~w~~[W](#)hole [g](#)Grains, ~~f~~[F](#)ish, ~~e~~[C](#)offee, ~~e~~[C](#)hocolate, [Healthy foods](#).

Introduction

Cardiac arrhythmia, also called cardiac dysrhythmia, is defined as any change from the normal sequence of electrical impulses. Although usually caused by cardiovascular ailments, cardiac arrhythmias themselves can lead to major cardiac complications, such as heart failure, stroke, or cardiac arrest¹. The two major arrhythmias of concern are atrial fibrillation (AF) and malignant ventricular arrhythmias. Atrial fibrillation is the most common arrhythmia encountered in clinical practice^{2,3}. It is estimated that by 2030, 14 to 17 million people in Europe, and 12.1 million people in the United States will be diagnosed with AF^{3,4}. Atrial fibrillation predisposes to major morbidities, including ischemic stroke, other systemic embolisms, dementia, heart failure, myocardial infarction, and chronic kidney disease^{5,6}. It also results in functional limitations, increased disability, and diminished quality of life⁷. The cardiovascular death rate is increased⁸. Its presence also increases overall mortality⁹. According to the US Centers for Disease Control and Prevention (CDC), AF was the underlying cause of death in 26,535 individuals in 2019 (in the USA)¹⁰. The overall healthcare use increases and the costs go up¹¹. The underlying mechanism is usually ectopic foci and reentry in the atrial tissue¹².

The second clinically important arrhythmia is malignant ventricular arrhythmias. These usually occur in the setting of structural heart diseases such as myocardial infarction, dilated non-

ischemic cardiomyopathy, and cardiac sarcoidosis¹³. They are most often seen with ischemic heart events¹⁴ and invariably result in deleterious hemodynamic complications¹⁵. These are also tied to a feared outcome - sudden cardiac death (SCD)¹³. Death attributable to cardiac causes and occurring within 1 hour of the onset of symptoms is defined as SCD¹⁶. [Reference no. 15 is missing???](#) Coronary heart disease (CHD) is responsible for almost 80% of cases of SCD, and SCD may, unfortunately, occur as its first manifestation¹⁷. Sudden cardiac death accounts for about 1 in 7.5 deaths in the United States¹⁸. SCD results from the occurrence of asystole and pulseless electrical activity or sustained ventricular arrhythmias, such as ventricular tachycardia and fibrillation¹⁹. Idiopathic ventricular arrhythmias, usually PVCs, although less ominous, may occur in normal hearts. In this population, they tend to occur in approximately 40% of adults on 24-h Holter monitoring²⁰. Ventricular arrhythmias result from several mechanisms – the three most common are abnormal automaticity, triggered activity, and reentry^{21,22}. Current guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden death have been published in 2015 by the European Society of Cardiology²³ and in 2017 by the American Heart Association (AHA)/American College of Cardiology/Heart Rhythm Society¹³. [The author need to review these cases worldwide through World Health Organization \(WHO\) literature.](#)

Cardiac arrhythmias arise due to enhanced or abnormal impulse generation (focal activity) and conduction disturbances (re-entry)^{24,25}. As mentioned above, underlying cardiac disease is by far the main substrate for these mechanisms and the development of AF and SCD. Other influences implicated include cardiotoxin exposure, medication side effects, cigarette smoke, stress, and the use of stimulant drugs²⁶⁻³⁰. Adherence to a low-risk lifestyle is associated with a low risk of AF and SCD³¹. Diet also plays an important role in both the primary prevention and secondary prevention of both arrhythmias, mainly by mitigating against structural heart disease³². The role of dietary components and supplements on the development and progression of AF and ventricular arrhythmias are discussed in this manuscript.

Discussion

Lifestyles

Lifestyles play an important role in human morbidity and mortality. The AHA Strategic Planning Task Force and Statistics Committee suggested an ideal cardiovascular lifestyle can be achieved by monitoring seven simple parameters, conveniently called the Life's Simple 7 (LS7)³³. These consist of 7 modifiable health behaviors and biological factors (smoking, body mass index [BMI], physical activity, diet, total cholesterol, blood pressure, and fasting blood glucose). It is estimated that LS7 compliance can improve cardiovascular health by 37%. The LS7 compliance also has an impact on AF – it portends a 57% lower risk³³.

Alcohol intake is not included in LS7. Traditionally, the accepted notion is that intake of low to moderate levels of alcohol is cardiovascular protective³⁴. However, recent data suggests that even a single drink of alcohol may not be safe for overall health^{35,36}. Wood et al analyzed 600,000 individuals and found that more than 1 drink a day increased all-cause mortality³⁵. Griswold et al. in 2018, in a systematic review and meta-regression analysis (28 million

individuals aged 15 to 49 years) reported that the lowest health loss was seen in individuals that had zero standard drinks per week³⁶. A recent brief from the World Heart Federation warned against the dangers of alcohol and proclaimed that ‘any level of alcohol consumption can lead to loss of healthy life’³⁷. Despite this alcohol-related data, there is ample evidence that following healthy lifestyles (including low to moderate intake of alcohol) provides significant health benefits^{38,39}. Li et al. estimated that the life expectancy at age 50 years was 29.0 years for women and 25.5 years for men who adopted zero low-risk lifestyle factors. In contrast, for those who adopted all 5 low-risk factors, the projected life expectancy at age 50 years was 43.1 years for women (a gain of 14 years) and 37.6 years for men (a gain of 12.2 years)³⁸. This manuscript deals with the role of one of these lifestyle factors, namely diet, in the pathogenesis of cardiac arrhythmias³³. Diet can influence these in two ways – by increasing body weight and by the individual actions of its ingredients³³.

Quantity of calories consumed

A body mass index (BMI) is commonly used to assign a bodyweight category in humans. A BMI ideally should be 18.5 kg/m² to 24.9 kg/m². A BMI between 25 kg/m² to 29.9 kg/m² is considered overweight, while at or >30 kg/m² is consistent with obesity³⁹. Proper intake of foods and beverages is crucial for a healthy body weight⁴⁰. This means that the balance between energy intake (calories taken in) and expenditure (calories burned) may need to be adjusted if the bodyweight is not ideal^{41,42}. A BMI between 18.5 kg/m² and 24.9 kg/m², once achieved, can be maintained by combining a healthy dietary pattern and with ≥150 minutes of moderate physical activity per week⁴³. In general, metabolic energy needs to be decreased by about 70-100 calories per day with each decade of adult life. Obesity has adverse effects on cardiac structure and function, leading to an increased risk of several cardiovascular diseases (CVDs) including hypertension, CHD, and heart failure (HF)⁴⁴. As mentioned before, underlying heart disease is a major risk factor for AF⁴⁵ and SCD⁴⁶.

Several observational cohort studies have highlighted obesity as an independent risk factor for the development of AF⁴⁷⁻⁵⁰. The ARIC (Atherosclerosis Risk In Communities) study estimated that almost 1 in 5 cases of AF could be attributable to overweight or obesity⁵¹. Wang et al calculated that there was a 4.7% increase in the risk of AF with each kg/m² rise in BMI⁵². Obesity also affects AF prognosis. Winkle et al observed a significantly higher risk of complications in AF patients with BMI ≥40 kg/m²⁵³, Shoemaker et al reported in their prospective study that BMI ≥40 kg/m² was associated with a greater risk of complications even after AF ablation⁵⁴.

~~Weight loss helps~~–Pathak et al. demonstrated that AF patients with significant intentional weight loss over a 5-year follow-up (>10%) had a 6-fold higher likelihood of arrhythmia-free survival, as compared with those with modest- to no-weight change (<3%)⁵⁵. Increasing evidence indicateds that obesity may contribute to the AF through several pathways such as increasing left atrial volume⁵⁶ and left atrial fibrosis^{57,58}. There is also an upregulation of inflammatory markers in these patients⁵⁹.

Obesity is also associated with malignant ventricular arrhythmias and SCD⁶⁰. The QT interval (on the surface electrocardiogram) represents the time from onset of ventricular depolarization to completion of repolarization. This interval, if prolonged (QTc value >450 ms in males and >460 ms in females, measured preferably in lead II or V5 on a standard 12-lead ECG), encourages ventricular arrhythmias and these may trigger torsades de pointes, ventricular fibrillation, and sudden cardiac death^{61,62}. Significant prolongation of QT (or QTc) is often seen in overweight and obese patients⁶³. Sabbag et al. and Vink et al. found that each 1 kg/m² increase in BMI was associated with a significant 4% increased adjusted risk for exercise-induced ventricular arrhythmias^{64,65}. The QTc is appreciably decreased with a substantial weight loss^{66,67}. Obesity in patients with malignant ventricular arrhythmias is associated with increased left ventricular (LV) diameter and mass⁶⁸, concentric LV hypertrophy⁶⁹, LV diastolic dysfunction⁷⁰, and fibrosis⁷¹. They also have repolarization abnormalities⁷². All these changes promote SCD.

Besides the quantitative risk of diet, the quality of diet also affects cardiac arrhythmias, especially by influencing the risk and progression of cardiovascular diseases.

Healthy Foods:

-Fruits and Vegetables

Fruits and vegetables have been associated with a benefit in virtually all CVDs^{73,74}. They provide potassium – low potassium in the serum is associated with an increase in the risk of lethal ventricular arrhythmias in patients with CVD. Potassium supplements tend to reduce blood pressure⁷⁵. It is well known that higher consumption of fruits and vegetables helps prevent potassium deficiency⁷⁶. Studies also suggest that high consumption of fruit and vegetables also reduces sympathetic and enhances parasympathetic activity, and this may help prevent SCD and arrhythmia^{77,78}. Grapefruit juice may markedly increase dronedarone HCl blood levels if taken in combination with the drug, resulting in excessive prolongation of the corrected QT interval, and resulting in ventricular arrhythmias, including torsade de pointes and cardiac arrest in clinical practice^{79,80}. Caution, therefore, needs to be exercised with imbibing grapefruit juice in patients who are on dronedarone.

-Nuts

Ingestion of nuts is CVD protective. Larsson et al. reported from a large prospective study that nut consumption may play a role in reducing the risk of AF. In their study of 61,364 Swedish adults (followed up for ~~up to~~ 17 years), data showed that the hazard ratio for AF was 0.97 for nut consumption 1-3 times/month, 0.88 for nut consumption 1-2 times/week, and 0.82 for nut consumption ≥ 3 times/week⁸¹. In this study, there was an 18% reduction in the risk of AF in those who consumed nuts ≥ 3 times/week. Consumption of nuts has been associated with improved serum cholesterol⁸², lower blood pressure⁸³, weight loss⁸⁴, decreased risk of diabetes⁸⁵, a lower incidence of ischemic heart disease⁸⁶, and a reduced risk of cardiovascular mortality⁸⁷. Nuts may beneficially influence cardiovascular health through their anti-inflammatory and antioxidant effects⁸⁸, and their role in improving endothelial function⁸⁹.

Nuts also appear to protect against malignant ventricular arrhythmias. Albert et al. reported that individuals in the US Physicians Health Study, who consumed nuts 2 or more times per week had a 57% reduced risk of SCD when compared with men who rarely or never consumed nuts. This reduction was noted even after controlling for known cardiac risk factors and other dietary factors. They found that the risk of SCD was 47% lower in men who consumed nuts ≥ 2 times per week compared with men who rarely or never consumed nuts⁹⁰.

-Whole grains/fiber

The consumption of whole-grains and dietary fiber, especially cereal fiber, reduces CVD morbidity and mortality⁹¹⁻⁹³. The fiber, vitamins, minerals, and various phytochemicals in whole-grains⁹⁴ decrease inflammation and oxidative stress⁹⁵. Inflammation and oxidative stress play a role in the pathophysiology of AF⁹⁶. Whole-grains are also a good source of dietary magnesium, and this may provide additional protection against AF⁹⁷. The specific benefit of whole grain intake on malignant ventricular arrhythmias is scarce, but diets such as the Mediterranean (see Part II), are rich in whole-grains and have a beneficial effect in protecting against SCD⁹⁸.

-Fish

The omega-3 fatty acids, including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are present in fish and marine products, with the highest concentrations in fish oils⁹⁹. These have been linked to a reduction in CVDs^{100,101}. Studies on fish oil intake in elderly patients have reported a reduced risk of developing AF¹⁰². Subsequent studies have, however, not supported this finding. A large-scale randomized study revealed no reduction in the incidence of postoperative AF with fish oil supplementation¹⁰³. A meta-analysis of published studies, by Mariani et al., found that fish oil and omega-3 polyunsaturated fatty acids (PUFA) intake had no AF protective effects¹⁰⁴. The effects of fish oil intake in preventing postoperative AF and in the secondary prevention of AF, therefore, remains unclear.

Their benefits in protecting against malignant ventricular arrhythmias are however clearer¹⁰⁵. Fish consumption was inversely associated with the risk of SCD in the Physicians' Health Study, with an apparent threshold effect at a consumption level of 1 fish meal per week¹⁰⁶. Consumption of fatty (higher EPA and DHA levels), but not lean fish was inversely associated with risk of SCD in the Zutphen Study¹⁰⁷. Both α -linolenic acid and marine n-3 fatty acids (EPA and DHA) were significantly inversely associated with the risk of SCD in the Nurses' Health Study^{108,109}. Albert et al and others have shown that increased consumption of fatty fish and n-3 PUFA appear to decrease the risk of SCD¹¹⁰⁻¹¹⁴, by reducing ventricular fibrillation¹¹². Their protective effects have also been seen in patients with implanted cardiac defibrillators (ICDs). In one study, ingestion of four 1 gm. capsules of n-3 PUFA was associated with a longer time to first ICD events and an overall decreased risk of having an ICD event¹¹⁵. Increased consumption of dark oily fish and n-3 PUFA, therefore, appear to decrease the risk of malignant ventricular arrhythmias and SCD^{112,113,116,117}. The AHA recommends consumption of two servings of fish per week (or supplementation with 1 g/day of EPA and DHA) for persons with no history of coronary heart disease and at least one serving of fish daily for those with known coronary heart disease¹¹⁸. A word of caution though - fish eaten (twice a week) should be low in environmental

contaminants such as methyl mercury, polychlorinated biphenyls, and dioxins. Fish typically high in these include - shark, swordfish, king mackerel, or tilefish (golden bass and golden snapper) and their intake should be minimized¹¹⁹. High-quality fish oil supplements usually do not contain these contaminants. Although omega-3 PUFA, are mainly found in fish and marine products, they can also be theoretically obtained from vegetable sources¹²⁰. Alpha-linoleic acid (ALA) present in certain vegetables (e.g., hemp, flax, walnut, and algae) is slowly metabolized to long-chain polyunsaturated ω -3 fatty acids¹²¹. However, this conversion into EPA and DHA is very limited, and clinical impact is probably very low.

Coffee/Tea/Energy Drinks

It is now well accepted that a consumption of 3-5 cups of coffee a day is associated with a lower risk of incident CHD and stroke¹²². Intake is also associated with a reduced CVD mortality¹²³ and all-cause mortality¹²⁴. In the past, it was postulated that coffee may be proarrhythmic because of its neurohormonal stimulation and sympathetic activation properties¹²⁵⁻¹²⁷. Several earlier studies had reported that acute and chronic coffee consumption contributed to the development of AF^{128,129}. Coffee was implicated in leading to less successful cardioversion in patients with hypertension¹³⁰. However, subsequent studies show that habitual intake of coffee is not related to incident AF¹³¹. On the contrary, recent studies suggest that coffee intake has a protective effect on AF¹³². Population-based studies have consistently demonstrated a reduction in AF with increasing levels of caffeine ingestion. Incident AF events in 57,053 participants followed for 13.5 years were lower in habitual coffee drinkers at all levels of consumption (Hazard Ratio or HR= 0.79 for 6 to 7 cups per day)¹³³. A meta-analysis of 6 prospective cohort studies with 228,465 participants similarly demonstrated an inverse relationship, with AF incidence decreasing by 6% for every 300 mg/day increment in regular caffeine intake¹³⁴. In a further meta-analysis of 115,993 patients, Caldeira et al. found that pooled results were consistent with a significant 13% reduction in incident AF risk¹³⁵. Klatsky et al. studied a population of 130,054 people and found that 3,137 subjects (2.4%) were hospitalized for arrhythmia over a 17.6 years' follow-up. In this study, caffeine intake was also inversely related to arrhythmia risk (including AF risk)¹³⁶. Most recent studies continue to corroborate the beneficial effects of coffee drinking on atrial arrhythmias. A recent study, published in 2019 in the Journal of the AHA, of men in the US Physicians' Health Study (N=18,960) suggested a lower risk of AF with consumption of 1 to 3 cups/day¹³⁷. An even more recent study (18,983 and 6,479 participants from the 'Seguimiento Universidad de Navarra' (SUN) and 'Prevención con Dieta Mediterranean' (PREDIMED) cohorts) respectively, found that intermediate levels of caffeinated coffee consumption (1-7 cups/week) reduced AF risk¹³⁸. In a prospective cohort study, Mendelian randomization failed to provide evidence that caffeine consumption increased arrhythmia risk. This study also showed that each additional cup of habitual coffee consumed was associated with a 3% lower risk of incident arrhythmia (HR= 0.97)¹³⁹. Coffee intake may also protect against ventricular arrhythmias – or at least may not be harmful. Although many earlier reports suggested a detrimental effect of coffee on these, it appears that animal studies were based on intake of very high doses of caffeine¹⁴⁰. In humans, consumption of about 400 mg a day or about 5 cups of coffee a day appears to be associated with no increase in ventricular arrhythmias. However, episodic coffee consumption has been known to trigger SCD¹⁴¹. Tea

consumption appears to reduce both atrial arrhythmias and ventricular arrhythmias¹⁴². In a meta-analysis, Zhang et al. found that consumption of 3 cups of tea per day significantly reduced the risk of cardiac death (relative risk 0.74)¹⁴³. Energy drinks may contain caffeine in significantly higher concentrations than in coffee and tea and may show pro-arrhythmogenic effects (both atrial and ventricular arrhythmias) in individuals with normal structural hearts¹⁴⁴.

-Chocolate

Chocolate consumption appears to be associated with a decreased risk of AF. Data from the Women's Health Study showed that moderate chocolate intake was associated with a 1%–14% lower rate of self-reported AF^{145,146}. More recently, Larsson et al. in a review of studies that included 180,454 participants and 16,356 AF cases, found that the hazard ratio was 0.97 per 2 servings/week increase in chocolate consumption and 0.96 for the highest versus lowest category of chocolate consumption¹⁴⁷. Inflammation plays a role in the development of AF and chocolate has anti-inflammatory actions¹⁴⁸. Further, chocolate also provides magnesium (100 calorie serving of dark chocolate contains 36 mg of magnesium) and this may also help in producing an antiarrhythmic effect¹⁴⁹. Chocolate intake has been known to protect against CVDs, and although no reliable study on chocolate use and ventricular arrhythmias could be found, it is tempting to associate its consumption with a lower incidence of SCD.

Conclusion

Healthy foodsDiet can play a significant role in decreasing the risk of CVD, including cardiac arrhythmias. Atrial fibrillation is a common atrial arrhythmia. It is the major cause of embolic stroke. Diet plays a significant role in preventing obesity, which is negatively associated with both serious atrial and malignant ventricular arrhythmias. A plant-based diet rich in fruits, vegetables, nuts, whole grains decreases the risk of AF. The data on fish intake and AF is unclear. Chocolate, coffee, and tea in moderate amounts appear to be beneficial. Energy drinks may however have significantly larger amount of caffeine, and this may make them arrhythmogenic. As far as malignant ventricular arrhythmias are concerned, a diet that helps prevent AF also appears to mitigate ventricular arrhythmias. The role of fish intake is more persuasive in its effects on the latter. The beneficial effects are primarily due to omega 3 PUFAs in fish. The role of chocolate is unclear while excessive caffeine intake via energy drinks may be harmful to ventricular arrhythmias. ~~Part II of this manuscript discusses the role of red meat, alcohol, micronutrients, and some common diets on cardiac arrhythmias. Any reference for part II????~~

References

1. American Heart Association About Arrhythmia. [(accessed on 1 December 2015)]. Available online: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/About-Arrhythmia_UCM_002010_Article.jsp#main.

2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119–25.
3. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. *Circulation*. 2014 Feb 25;129(8):837–47. doi: 10.1161/CIRCULATIONAHA.113.005119.
4. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. *Clin Epidemiol*. 2014;6:213–20. doi: 10.2147/CLEP.S47385. doi: 10.2147/CLEP.S47385.
5. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. *Am J Cardiol*. 2013 Oct 15;112(8):1142–7. doi: 10.1016/j.amjcard.2013.05.063.
6. Chen LY, Norby FL, Gottesman RF, Mosley TH, Soliman EZ, et al. Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20 Years: The ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). *J Am Heart Assoc*. 2018 Mar 7;7(6):e007301. doi: 10.1161/JAHA.117.007301.
7. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014 Feb 25;129(8):837–47. doi: 10.1161/CIRCULATIONAHA.113.005119.
8. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139–e596. DOI: 10.1161/CIR.0000000000000757.
9. Kirchhof P., Auricchio A., Bax J., Crijns H., Camm J., et al. Outcome parameters for trials in atrial fibrillation: executive summary. *Eur. Heart J*. 2007;28(22):2803–2817. doi: 10.1093/eurheartj/ehm358.
10. Centers for Disease Control and Prevention, National Center for Health Statistics. About Multiple Cause of Death, 1999–2019. CDC WONDER Online Database website. Atlanta, GA: Centers for Disease Control and Prevention; 2019. Accessed February 1, 2021.
11. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. *Value Health*. 2012 Mar-Apr;15(2):240–8. doi: 10.1016/j.jval.2011.09.009.
12. Haïssaguerre M, Jaïs P, Shah D C, Takahashi A, Hocini M, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N.Engl. J. Med*. 1998 Sep 03;339 (10):659–66.
13. Al-Khatib S.M., Stevenson W.G., Ackerman M.J., Bryant W.J., Callans D.J., et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2018;138:e272–e391. doi: 10.1161/CIR.0000000000000549.
14. Lo R., Chia K.K.M., Hsia H.H. Ventricular Tachycardia in Ischemic Heart Disease. *Card. Electrophysiol. Clin*. 2017;9:25–46. doi: 10.1016/j.ccep.2016.10.013.
15. Markman T.M., Nazarian S. Treatment of Ventricular Arrhythmias: What's New? *Trends Cardiovasc. Med*. 2019;29:249–261. doi: 10.1016/j.tcm.2018.09.014.

16. Katritsis DG, Gersh BJ, Camm AJ. A clinical perspective on sudden cardiac death. *Arrhythm Electrophysiol Rev.* 2016;5:177–182. DOI: 10.15420/aer.2016:11:2.
17. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. *J Am Coll Cardiol.* 2006;47(6):1161–1166.
18. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, et al.; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. *Circulation.* 2019;139:e56–e528.
19. Zheng Z-J, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. *Circulation.* 2001;104:2158–63.
20. Hingorani P., Karnad D.R., Rohekar P., Kerkar V., Lokhandwala Y.Y., Kothari S. Arrhythmias Seen in Baseline 24-Hour Holter ECG Recordings in Healthy Normal Volunteers During Phase 1 Clinical Trials. *J. Clin. Pharm.* 2016;56:885–893. doi: 10.1002/jcph.679.
21. Wit A.L. Cellular Electrophysiologic Mechanisms of Cardiac Arrhythmias. *Cardiol. Clin.* 1990;8:393–409. doi: 10.1016/S0733-8651(18)30347-3.
22. Cabo C., Wit A.L. Cellular Electrophysiologic Mechanisms of Cardiac Arrhythmias. *Cardiol. Clin.* 1997;15:517–538. doi: 10.1016/S0733-8651(05)70360-X.
23. Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., et al. 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) *Eur. Heart J.* 2015;36:2793–2867. doi: 10.1093/eurheartj/ehv316.
24. Weiss JN, Garfinkel A, Karagueuzian HS, Nguyen TP, Olcese R, Chen PS, Qu Z. Perspective: a dynamics-based classification of ventricular arrhythmias. *J Mol Cell Cardiol.* 2015; 82:136–152.
25. Nattel S, Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. *Nat Rev Cardiol.* 2016; 13:575–590. doi: 10.1038/nrcardio.2016.118.
26. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. *Nat Rev Cardiol.* 2020 Aug;17(8):474-502. doi: 10.1038/s41569-020-0348-1.
27. D'Alessandro A, Boeckelmann I, Hammwhoner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. *Eur J Prev Cardiol.* 2012;19(3):297-305.
28. Krijthe BP, Heeringa J, Hofman A, Franco OH, Stricker BH. Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: a population-based follow-up study. *BMJ Open.* 2014;4(4):e004059.
29. Buckley U, Shivkumar K. Stress-induced cardiac arrhythmias: The heart-brain interaction. *Trends Cardiovasc Med.* 2016 Jan;26(1):78-80. doi: 10.1016/j.tcm.2015.05.001.
30. Bébarová M, Horáková Z, Kula R. Addictive drugs, arrhythmias, and cardiac inward rectifiers. *Europace.* 2017 Mar 1;19(3):346-355. doi: 10.1093/europace/euw071.

31. Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, Albert CM. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. *JAMA*. 2011 Jul 6;306(1):62-9. doi: 10.1001/jama.2011.907..
32. Alice H. Lichtenstein, Lawrence J. Appel, Maya Vadiveloo, Penny M. Kris-Etherton, Casey M. Rebholz, et al. Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement. *Circulation*. 2021;144:e472–e487. DOI: 10.1161/CIR.0000000000001031.
33. Lloyd-Jones Dm, Hong Y, Labarthe D, Mozaffarian D, Appel Lj, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*, 121, 586–613.
34. Piano MR. Alcohol's Effects on the Cardiovascular System. *Alcohol Res*. 2017;38(2):219-241.
35. Wood AM, Stephen Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet*, 391, 1513–1523.
36. Griswold Mg, Fullman N, Hawley C, Arian N, Zimsen SRM, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*, 392, 1015–1035.
37. <https://world-heart-federation.org/news/no-amount-of-alcohol-is-good-for-the-heart-says-world-heart-federation/>
38. Li Y, Pan A, Wang DD, Liu X, Dhana K, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. *Circulation*. 2018 Jul 24;138(4):345-355. doi: 10.1161/CIRCULATIONAHA.117.032047.
39. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee.
40. U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. Washington DC: U.S. Department of Health and Human Services; 2015.
41. Harvey-Berino J. Calorie restriction is more effective for obesity treatment than dietary fat restriction. *Ann Behav Med*. 1999 Spring;21(1):35-9. doi: 10.1007/BF02895031.
42. Lecheminant JD, Gibson CA, Sullivan DK, Hall S, Washburn R, et al. Comparison of a low carbohydrate and low-fat diet for weight maintenance in overweight or obese adults enrolled in a clinical weight management program. *Nutr J*. 2007 Nov 1;6:36. doi: 10.1186/1475-2891-6-36.
43. Fock KM, Khoo J. Diet and exercise in management of obesity and overweight. *J Gastroenterol Hepatol*. 2013 Dec;28 Suppl 4:59-63. doi: 10.1111/jgh.12407.
44. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on

Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973.

45. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol*. 2010; 55:725-731.
46. Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. *Eur J Epidemiol*. 2018;33:711–722. doi: 10.1007/s10654-017-0353-9.
47. Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. *JAMA*. 2004;292:2471–7. doi: 10.1001/jama.292.20.2471.
48. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Med*. 2005;118:489–95. doi: 10.1016/j.amjmed.2005.01.031.
49. Foy AJ, Mandrola J, Liu G, Naccarelli GV. Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults. *Am J Cardiol*. 2018;121:1072–5. doi: 10.1016/j.amjcard.2018.01.019.
50. Lee H, Choi EK, Lee SH et al. Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study. *Int J Cardiol*. 2017;240:221–7. doi: 10.1016/j.ijcard.2017.03.103.
51. R.R. Huxley, F.L. Lopez, A.R. Folsom, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*, 123 (2011), pp. 1501-1508.
52. Wang YC, McPherson K, Marsh T et al. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet*. 2011;378:815–25. doi: 10.1016/S0140-6736(11)60814-3.
53. Winkle RA, Mead RH, Engel G, et al. Impact of obesity on atrial fibrillation ablation: patient characteristics, long-term outcomes, and complications. *Heart Rhythm*. 2017;14(6):819-827.
54. Shoemaker MB, Muhammad R, Farrell M, et al. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. *Am J Cardiol*. 2013;111(3):368-373.
55. R.K. Pathak, M.E. Middeldorp, M. Meredith, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY) *J Am Coll Cardiol*, 65 (2015), pp. 2159-2169.
56. Stritzke J, Markus MR, Duderstadt S et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J Am Coll Cardiol*. 2009;54:1982–9. doi: 10.1016/j.jacc.2009.07.034.

57. Venteclef N, Guglielmi V, Balse E et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokinases. *Eur Heart J*. 2015;36:795–80a. doi: 10.1093/eurheartj/ehv099.
58. Chen MC, Chang JP, Liu WH et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. *Am J Cardiol*. 2008;102:861–5. doi: 10.1016/j.amjcard.2008.05.038.
59. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. *Circ J*. 2015;79:495–502. doi: 10.1253/circj.CJ-15-0138.
60. Plourde B, Sarrazin JF, Nault I, Poirier P. Sudden cardiac death and obesity. *Expert Rev Cardiovasc Ther*. 2014 Sep;12(9):1099–110. doi: 10.1586/14779072.2014.952283.
61. Y.G. Yap, A.J. Camm. Drug induced QT prolongation and torsades de pointes. *Heart*, 89 (2003), pp. 1363–1372.
62. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol*. 2006 Jan 17;47(2):362–7. doi: 10.1016/j.jacc.2005.08.067.
63. Curione M, Tego A, Capoccia D, Varrenti M, Baiocco E, Salvatore S, Maglio C, Leonetti F. Prediction of QTc length as function of BMI: a clinical tool to establish arrhythmias risk in obesity. *Clin Ter*. 2011;162(6):e155–9.
64. Sabbag A, Sidi Y, Kivity S, Beinart R, Glikson M, Segev S, Goldenberg I, Maor E. Obesity and exercise-induced ectopic ventricular arrhythmias in apparently healthy middle aged adults. *Eur J Prev Cardiol*. 2016 Mar;23(5):511–7. doi: 10.1177/2047487315591442.
65. Vink AS, Neumann B, Lieve KVV, Sinner MF, Hofman N, et al. Determination and interpretation of the QT interval. *Circulation*. 2018; 138:2345–2358. doi: 10.1161/CIRCULATIONAHA.118.033943.
66. Seyfeli E, Duru M, Kuvandik G, Kaya H, Yalçın F. Effect of weight loss on QTc dispersion in obese subjects. *Anadolu Kardiyol Derg*. 2006 Jun;6(2):126–9.
67. Omran J, Firwana B, Koerber S, Bostick B, Alpert MA. Effect of obesity and weight loss on ventricular repolarization: a systematic review and meta-analysis. *Obes Rev*. 2016 Jun;17(6):520–30. doi: 10.1111/obr.12390.
68. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. *Am J Cardiol*. 1992;70:921–924. doi: 10.1016/0002-9149(92)90739-l.
69. Duflo J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. *Am Heart J*. 1995;130:306–313. doi: 10.1016/0002-8703(95)90445-x.
70. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. *J Am Coll Cardiol*. 2011;57:1368–1374. doi: 10.1016/j.jacc.2010.10.042.

71. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. *JAMA*. 2013;309:896–908. doi: 10.1001/jama.2013.136.
72. Brenyo A, Pietrasik G, Barsheshet A, Huang DT, Polonsky B, et al. QRS fragmentation and the risk of sudden cardiac death in MADIT II. *J Cardiovasc Electrophysiol*. 2012;23:1343–1348. doi: 10.1111/j.1540-8167.2012.02390.x.
73. Zhao CN, Meng X, Li Y, et al. Fruits for Prevention and Treatment of Cardiovascular Diseases. *Nutrients*. 2017;9(6):598. Published 2017 Jun 13. doi:10.3390/nu9060598.
74. Bondonno CP, Dalgaard F, Blekkenhorst LC, et al. Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study. *Eur J Epidemiol*. Published online April 21, 2021. doi: 10.1007/s10654-021-00747-3
75. Newberry SJ, Chung M, Anderson CAM, Chen C, Fu Z, Tang A, et al. Sodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jun. Report No.: 18-EHC009-EF.
76. He FJ, MacGregor GA. Beneficial effects of potassium on human health. *Physiol Plant*. 2008 Aug;133(4):725-35. doi: 10.1111/j.1399-3054.2007.01033.x.
77. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events: The Framingham Heart Study. *Circulation* 1996;94:2850–5.
78. Tapanainen JM, Thomsen PE, Kober L, et al. Fractal analysis of heart rate variability and mortality after an acute myocardial infarction. *Am J Cardiol* 2002;90:347–52.
79. Agosti S, Casalino L, Bertero G, et al. A dangerous fruit juice. *Am J Emerg Med* 2012;30:248.e5–248.e8.
80. Kao DP, Hiatt WR, Krantz MJ. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. *Pharmacotherapy* 2012. June 28.
81. Larsson SC, Drca N, Björck M, Bäck M, Wolk A. Nut consumption and incidence of seven cardiovascular diseases. *Heart*. 2018 Oct;104(19):1615-1620. doi: 10.1136/heartjnl-2017-312819.
82. Sabaté J, Oda K, Ros E: Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. *Arch Intern Med* 2010, 170:821-827.
83. Djousse L, Rudich T, Gaziano JM: Nut consumption and risk of hypertension in US male physicians. *Clin Nutr* 2009, 28:10-14.
84. Bes-Rastrollo M, Sabate J, Gomez-Gracia E, Alonso A, Martinez JA, MartinezGonzalez MA: Nut consumption and weight gain in a Mediterranean cohort: the SUN study. *Obesity (Silver Spring)* 2007, 15:107-116.
85. Jiang R, Manson JE, Stampfer MJ, Liu S, Willett WC, Hu FB: Nut and peanut butter consumption and risk of type 2 diabetes in women. *JAMA* 2002, 288:2554-2560.
86. Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. *Am J Clin Nutr*. 2014 Jul;100(1):256-69. doi: 10.3945/ajcn.113.076109.

87. Albert CM, Gaziano J, Willett WC, Manson JE: Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. *Arch Intern Med* 2002, 162:1382-1387.
88. Ros E. Health benefits of nut consumption. *Nutrients* 2010;2:652-82.
89. Xiao Y, Huang W, Peng C, et al. Effect of nut consumption on vascular endothelial function: A systematic review and meta-analysis of randomized controlled trials. *Clin Nutr* 2017.
90. Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. *Arch Intern Med.* 2002 Jun 24;162(12):1382-7. doi: 10.1001/archinte.162.12.1382.
91. Liu S, Sesso HD, Manson JE, Willett WC, Buring JE. Is intake of breakfast cereals related to total and cause-specific mortality in men? *Am J Clin Nutr* 2003;77:594-9.
92. Steffen LM, Jacobs DR, Jr, Stevens J, Shahar E, Carithers T, Folsom AR. Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Clin Nutr* 2003;78:383-90.
93. Jacobs DR, Jr, Andersen LF, Blomhoff R. Whole-grain consumption is associated with a reduced risk of noncardiovascular, noncancer death attributed to inflammatory diseases in the Iowa Women's Health Study. *Am J Clin Nutr* 2007;85:1606-14.
94. US Department of Agriculture Dietary guidelines for Americans 2005. Washington, DC: US Department of Agriculture, 2005.
95. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. *Am J Cardiol* 2003;92:1335-9.
96. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. *Heart Rhythm* 2010;7:438-44.
97. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, et al. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. *Am J Clin Nutr.* 2014 Feb;99(2):344-51. doi: 10.3945/ajcn.112.056135.
98. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, et al. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. *Am J Clin Nutr.* 2014 Feb;99(2):344-51. doi: 10.3945/ajcn.112.056135.
99. Calder P.C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim. Et Biophys. Acta BBA Mol. Cell Biol. Lipids.* 2015;1851:469-484. doi: 10.1016/j.bbalip.2014.08.010.
100. GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet.* 1999 Aug 7;354(9177):447-55.
101. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2008; 372: 1223-1230.

102. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, Siscovick DS: Fish intake and risk of incident atrial fibrillation. *Circulation*, 2004; 110: 368-373.
103. Mozaffarian D, Wu JH, de Oliveira Otto MC, Sandesara CM, Metcalf RG, et al. Fish oil and post-operative atrial fibrillation: a metaanalysis of randomized controlled trials. *J Am Coll Cardiol*, 2013; 61: 2194-2196.
104. Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, Tognoni G, Macchia A: N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc*, 2013; 2: e005033.
105. Riemersma RA, Sargent CA. Dietary fish oil and ischaemic arrhythmias. *J Intern Med Suppl*. 1989;731:111-6. doi: 10.1111/j.1365-2796.1989.tb01444.x.
106. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. *JAMA*. 1998;279:23–28. DOI: 10.1001/jama.279.1.23.
107. Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. *Eur Heart J*. 2008;29:2024–2030. DOI: 10.1093/eurheartj/ehn294.
108. Chiuve SE, Rimm EB, Sandhu RK, Bernstein AM, Rexrode KM, Manson JE, Willett WC, Albert CM. Dietary fat quality and risk of sudden cardiac death in women. *Am J Clin Nutr*. 2012;96:498–507. DOI: 10.3945/ajcn.112.040287.
109. Albert CM, Oh K, Whang W, Manson JE, Chae CU, et al. Dietary alpha-linolenic acid intake and risk of sudden cardiac death and coronary heart disease. *Circulation*. 2005;112:3232–3238.
110. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med*. 2002;346:1113-8.
111. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 2002;106:2747–57.
112. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n–3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n–3 fish oils. *Circulation* 2003;107:2646–52.
113. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 2002;106:2747–57.
114. Wang C, Harris WS, Chung M, et al. n–3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr* 2006;84:5–17.
115. Leaf A. Historical overview of n-3 fatty acids and coronary heart disease. *Am J Clin Nutr*. 2008 Jun;87(6):1978S-80S. doi: 10.1093/ajcn/87.6.1978S.
116. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, et al. Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects

- by fish oil n-3 fatty acid intake. *Circulation*. 2005 Nov 1;112(18):2762-8. doi: 10.1161/CIRCULATIONAHA.105.549527.
117. Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. *Eur Rev Med Pharmacol Sci*. 2015;19(3):441-5.
118. www.heart.org.
119. U.S. Food and Drug Administration. What you need to know about mercury in fish and shellfish. FDA/CFSAN Consumer Advisory. EPA-823-R-04-005. March 2004.
120. Calder P.C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim. Et Biophys. Acta BBA Mol. Cell Biol. Lipids*. 2015;1851:469–484. doi: 10.1016/j.bbalip.2014.08.010.
121. Komarnytsky S., Rathinasabapathy T., Wagner C., Metzger B., Carlisle C., et al. S. Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils. *Int. J. Mol. Sci*. 2021;22:5479. doi: 10.3390/ijms22115479.
122. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. *Circulation* 2014;129:643-59. 10.1161/CIRCULATIONAHA.113.005925.
123. Grosso G, Micek A, Godos J, et al. Coffee consumption and risk of all-cause, cardiovascular, and cancer mortality in smokers and non-smokers: a dose-response meta-analysis. *Eur J Epidemiol* 2016;31:1191-205. 10.1007/s10654-016-0202-2.
124. J.H. O'Keefe, S.K. Bhatti, H.R. Patil, J.J. DiNicolantonio, S.C. Lucan, C.J. Lavie. Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. *J Am Coll Cardiol*, 62 (2013), pp. 1043-1051.
125. Strubelt O, Diederich KW. Experimental treatment of the acute cardiovascular toxicity of caffeine. *J Toxicol Clin Toxicol* 1999;37:29–33.
126. Shen J, Johnson VM, Sullivan LM, Jacques PF, Magnani JW, Lubitz SA, et al. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. *Am J Clin Nutr*. 2011;93:261–6. 10.3945/ajcn.110.001305.
127. Bhawe PD, Hoffmayer K. Caffeine and atrial fibrillation: friends or foes? *Heart*. 2013;99:1377–8.
128. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. *J Intern Med* 2001;250:382–9.
129. Mattioli AV, Bonatti S, Zennaro M, Melotti R, Mattioli G. Effect of coffee consumption, lifestyle and acute life stress in the development of acute lone atrial fibrillation. *J Cardiovasc Med (Hagerstown)* 2008;9:794–8.
130. Mattioli AV, Farinetti A, Miloro C, Pedrazzi P, Mattioli G. Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients. *Nutr Metab Cardiovasc Dis (Epub ahead of print 16 February 2010))*.
131. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Clin Nutr* 2005;81:578–82.
132. Bazal P, Gea A, Navarro AM, Salas-Salvadó J, Corella D, et al. Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts. *Eur J Prev Cardiol*. 2020 Mar 4;:2047487320909065. doi: 10.1177/2047487320909065.

133. E. Mostofsky, M.B. Johansen, S. Lundbye- Christensen, A. Tjønneland, M.A. Mittleman, K. Overvad. Risk of atrial fibrillation associated with coffee intake: findings from the Danish Diet, Cancer, and Health study. *Eur J Prev Cardiol*, 23 (2016), pp. 922-930.
134. Aleksandr Voskoboinik and Jonathan M. Kalman and Peter M. Kistler. ,Caffeine and Arrhythmias: Time to Grind the Data. *JACC: Clinical Electrophysiology*. <https://www.sciencedirect.com/science/article/pii/S2405500X18300756>}, doi: <https://doi.org/10.1016/j.jacep.2018.01.012>.
135. D. Caldeira, C. Martins, L.B. Alves, H. Pereira, J.J. Ferreira, J. Costa. Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. *Heart*, 99 (2013), pp. 1383-1389.
136. Klatsky A.L., A.S. Hasan, M.A. Armstrong, N. Udaltsova, C. Morton. Coffee, caffeine, and risk of hospitalization for arrhythmias. *Perm J*, 15 (2011), pp. 19-25.
137. Bodar V, Chen J, Gaziano JM, Albert C, Djoussé L. Coffee Consumption and Risk of Atrial Fibrillation in the Physicians' Health Study. *J Am Heart Assoc*. 2019 Aug 6;8(15):e011346. doi: 10.1161/JAHA.118.011346.
138. Bazal P, Gea A, Navarro AM, Salas-Salvadó J, Corella D, et al. Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts. *Eur J Prev Cardiol*. 2021 May 22;28(6):648-657. doi: 10.1177/2047487320909065.
139. Kim EJ, Hoffmann TJ, Nah G, Vittinghoff E, Delling F, Marcus GM. Coffee Consumption and Incident Tachyarrhythmias: Reported Behavior, Mendelian Randomization, and Their Interactions. *JAMA Intern Med*. 2021 Sep 1;181(9):1185-1193. doi: 10.1001/jamainternmed.2021.3616.
140. Priccila Zuchinali, Paula A. B. Ribeiro, Maurício Pimentel, Priscila R. et al. Effect of caffeine on ventricular arrhythmia: a systematic review and meta-analysis of experimental and clinical studies, *EP Europace*, Volume 18, Issue 2, February 2016, Pages 257–266, <https://doi.org/10.1093/europace/euv261>.
141. Čulić V, AlTurki A, Proietti R. Public health impact of daily life triggers of sudden cardiac death: A systematic review and comparative risk assessment. *Resuscitation*. 2021 May;162:154-162. doi: 10.1016/j.resuscitation.2021.02.036.
142. D.C. Liu, J.J. Yan, Y.N. Wang, et al. Low-dose green tea intake reduces incidence of atrial fibrillation in a Chinese population. *Oncotarget*, 7 (2016), pp. 85592-85602.
143. C. Zhang, Y.Y. Qin, X. Wei, F.F. Yu, Y.H. Zhou, J. He. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. *Eur J Epidemiol*, 30 (2015), pp. 3-13.
144. A. Enriquez, D.S. Frankel. Arrhythmogenic effects of energy drinks. *J Cardiovasc Electrophysiol*, 28 (2017), pp. 711-717.
145. Conen D, Chiuve SE, Everett BM, et al. Caffeine consumption and incident atrial fibrillation in women. *Am J Clin Nutr*. 2010;92:509–14.
146. Mostofsky E, Berg Johansen M, Tjønneland A, Chahal HS, Mittleman MA, Overvad K. Chocolate intake and risk of clinically apparent atrial fibrillation: the Danish Diet, Cancer, and Health Study. *Heart*. 2017 Aug;103(15):1163-1167. doi: 10.1136/heartjnl-2016-310357.

147. Larsson SC, Drca N, Jensen-Urstad M, Wolk A. Chocolate consumption and risk of atrial fibrillation: Two cohort studies and a meta-analysis. *Am Heart J*. 2018 Jan;195:86-90. doi: 10.1016/j.ahj.2017.09.013.
148. Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation. *Nature reviews Cardiology*. 2015;12:230–43.
149. Katz DL, Doughty K, Ali A. Cocoa and chocolate in human health and disease. *Antioxidants & redox signaling*. 2011;15:2779–811.

UNDER PEER REVIEW